Press release
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in Relapsed/Refractory Acute Myeloid Leukemia Research. Learn more about our innovative pipeline today! @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
* June 2024:- Ryvu Therapeutics SA- A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent.
* June 2024:- LLS PedAL Initiative LLC- A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
* DelveInsight's Relapsed/Refractory Acute Myeloid Leukemia pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/Refractory Acute Myeloid Leukemia treatment.
* The leading Relapsed/Refractory Acute Myeloid Leukemia Companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen , and others.
* Promising Relapsed/Refractory Acute Myeloid Leukemia Therapies such as UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib , and others.
Stay informed about the cutting-edge advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatments. Download for updates and be a part of the revolution in oncology care @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs Profile
* APG-2575: Ascentage Pharma
APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenstrom macroglobulinemia, acute myeloid leukemia, follicular lymphoma).
* CLN 049: Cullinan Oncology
CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.
* Lanraplenib: Kronos Bio
Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.
Learn more about Relapsed/Refractory Acute Myeloid Leukemia Drugs opportunities in our groundbreaking Relapsed/Refractory Acute Myeloid Leukemia Research and development projects @ Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Discover the latest advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Relapsed/Refractory Acute Myeloid Leukemia Market Drivers
* Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Relapsed/Refractory Acute Myeloid Leukemia Market.
Relapsed/Refractory Acute Myeloid Leukemia Market Barriers
* However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Relapsed/Refractory Acute Myeloid Leukemia Market growth.
Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
* Coverage- Global
* Relapsed/Refractory Acute Myeloid Leukemia Companies- Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
* Relapsed/Refractory Acute Myeloid Leukemia Therapies- UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.
* Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Relapsed/Refractory Acute Myeloid Leukemia Pipeline on our website @ Relapsed/Refractory Acute Myeloid Leukemia Drugs and Companies [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Relapsed/refractory acute myeloid leukemia (AML): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Relapsed/refractory acute myeloid leukemia (AML)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* APG-2575: Ascentage Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CLN 049: Cullinan Oncology
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Relapsed/refractory acute myeloid leukemia (AML) Key Companies
* Relapsed/refractory acute myeloid leukemia (AML) Key Products
* Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
* Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
* Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
* Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
* Relapsed/refractory acute myeloid leukemia (AML) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=relapsedrefractory-acute-myeloid-leukemia-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3560466 • Views: …
More Releases from ABNewswire
The Science of Sharper Thinking: Sustainable Ways to Support Memory and Mental P …
In an economy powered by ideas, clarity of thought is a competitive edge. The ability to retain information, connect patterns, recall details, and stay focused under pressure influences everything from leadership decisions to academic achievement. Memory is no longer just a background cognitive function-it's central to productivity, creativity, and long-term success.
In an economy powered by ideas, clarity of thought is a competitive edge. The ability to retain information, connect patterns,…
Travel-Loving Women Find Their Perfect Beach Style With Beach Groove Swimwear's …
Beach Groove Swimwear caters to the modern travel enthusiast with versatile swimwear collections designed for various vacation scenarios. From tropical getaways to poolside parties, the brand offers women a comprehensive selection that combines fashion-forward designs with practical performance features.
For women who prioritize travel and beach experiences, finding the right swimwear can make or break a vacation. Beach Groove Swimwear has emerged as a specialized retailer that understands the unique needs…
How J&J Accessories Uses Customer Behavior Analytics to Stay Ahead of Retail Tre …
In an era where many retailers struggle with excess inventory and declining margins, J&J Accessories has built a thriving e-commerce business by letting data guide every product decision. The company's analytical approach to understanding customer behavior has enabled it to maintain a fresh, relevant catalog that resonates with time-pressed professionals. This strategy positions the brand as a model for the next generation of agile online retail.
The retail industry has long…
Small Business Champion Rnispir LLC Showcases Products from Veteran and Women-Ow …
Rnispir LLC is making waves in the e-commerce sector by prioritizing partnerships with underrepresented business owners across America. With a network exceeding 400 U.S. suppliers, the company spotlights products from veterans, women entrepreneurs, and family operations, offering customers distinctive gourmet foods, outdoor equipment, and home goods unavailable through conventional retail channels.
The American small business landscape faces unprecedented challenges, from supply chain disruptions to competition with multinational corporations. Rnispir LLC addresses…
More Releases for Acute
Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,…
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but…
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to…
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth…
